About us
What we do
History
Where we work
Northern Ireland
Republic of Ireland
Scotland
Wales
North West England
Trent, Northern and Yorkshire
West Midlands
South West and Wessex
Southern England
Committee Structure
Executive and Council
Publication and Communications
National Meetings Committee
Education, Training and Workforce
Scientific Affairs and Clinical Practice
Immunology Professional Committee
Microbiology Professional Committee
President
Our Members
Equality, Diversity and Inclusion
Federation of Clinical Scientists
Staff Team
Join us
Healthcare professionals
Corporate members
European Registration
Our Resources
News
Science Knowledge Hub
Audits
Analyte Monographs
Electives
NICE Guideline Summaries
Endocrine Guideline Summaries
Measurement Verification
Internal Quality Control for Networked Analysers
Careers, Education and Training
Policy and Media
Publications
Annual Report and Accounts
Annals of Clinical Biochemistry
ACB Books
Archive
Events and Awards
Event calendar
Past ACB Events
Scholarships and Grants
Scientific Scholarships
Education Travel Grants
Benevolent Fund
C P Stewart Memorial Fund
Awards and Prizes
Emeritus, Fellow, Honorary and Friends
President's Shield
National Conference Awards
Members Papers
Don Henderson Award
CSci
National Meetings
ACB Focus 2021 Abstract Submission
Search
Login
You're here:
Home
Our Resources
TA288 Dapagliflozin in combination therapy for treating type 2 diabetes
NICE Guideline Summary
01 Jun 2013
by Chris Parker
TA288 Dapagliflozin in combination therapy for treating type 2 diabetes
Date of Review: July 2018
Date of Publication June 2013
ta288-dapagliflozin-in-combination-therapy-for-treating-type-2-diabetes.pdf
43 KB
Download
Authors
Chris Parker
Return to listing
